Development of a world-leading preclinical drug development company specialising in ophthalmology through innovative state-of-the-art preclinical models and expert provision of data interpretation.

糖尿病性视网膜病变（DR）和视网膜相关性黄斑变性（AMD）（本文称为视网膜疾病）是全球视力丧失的主要原因，影响超过3亿人。目前视网膜疾病的治疗策略是有限的，在有前途的药物的后期临床试验中观察到的疗效较差。这是由于疾病的临床前模型不佳。生物技术和制药公司的总研发（R&D）中有50%以上是外包的。在ICURe期间进行的广泛市场研究揭示了导致临床前药物开发不合格的关键因素。其中包括：过时和不适当的临床前模型;次优的研究设计;缺乏协作数据解释;缺乏技术质量和糟糕的客户服务提供。MediNect建立在30年的视网膜疾病临床前模型密集研发的基础上，提供针对目前市场上无法获得的疾病特征的最先进模型。MediNect拥有丰富的技术和解释知识，可提供最佳的研究设计、实用技术和数据解释。MediNect将作为一家公司，为临床前药物开发提供合作方法，并在10种成熟的视网膜疾病模型和两种新型模型中测试新药。经行业标准验证，糖尿病黄斑缺血（diabetic macular ischaemia，EAI）和视网膜下纤维化（sub-retinal fibrosis，SRF）模型将分别用于更深入地了解针对晚期视网膜疾病的新药。我们的新模型比目前使用复制早期疾病特征的模型的方法优越上级。MediNect有一个五个国家的目录-最先进的转基因模型和五个正在开发中的模型，这些模型针对视网膜疾病特征的未满足区域，上级现有方法，将巩固MediNect作为眼科药物开发研究市场领导者的地位。MediNect的世界领先专家团队和MediNect将为研究人员提供以客户为中心的黄金标准服务，提供肿瘤学-CRO标准通信流，研究计划提供对药物开发的更深入了解。MediNect将帮助开发更好的视力恢复药物的迫切需求，帮助全球6000万晚期视网膜疾病患者。

Diabetic Retinopathy (DR) and Age-related macular degeneration (AMD), termed retinal disease herein, are the leading cause of vision loss worldwide, affecting over 300 million people. Current treatment strategies for retinal disease are limited, with poor efficacy observed in late-stage clinical trials of promising drugs. This is attributed to poor preclinical models of disease.Over 50% of the total research and development (R&D) by biotechnology and pharmaceutical companies is outsourced. Extensive market research conducted during ICURe, revealed key factors contributing to substandard preclinical drug development. These included: outdated and inappropriate preclinical models; suboptimal study design; a lack of collaborative data interpretation; a lack of technical quality and a poor customer service provision.MediNect builds on 30 years' intensive R&D of preclinical models in retinal disease to deliver state-of-the-art models that target disease features currently not available to the market. MediNect has a wealth of technical and interpretive know-how, which provides optimal study design, practical technique and data interpretation. MediNect will function as a company to offer a collaborative approach to preclinical drug development, with access to test novel drugs in ten well-established models of retinal disease and two novel models. Validated to industry standard, the diabetic macular ischaemia (DMI) and sub-retinal fibrosis (SRF) model will be used to give greater insight into novel drugs targeting late-stage retinal disease, respectively. Our novel models are superior to current methods that use models that replicate early-stage disease features.In addition, MediNect has a catalogue of five state-of-the-art genetically modified models and five in development that target unmet areas of retinal disease features that are superior to current methods and will cement MediNect's position as market leaders in ophthalmology drug development research.MediNect's team of world leading experts and researchers will be complimented by a gold-standard client-focused offering to deliver oncology-CRO standard communication streams, study planning providing greater insight into drug development.MediNect will help the urgent need for development of better vision-restoring drugs, helping 60 million people worldwide suffering from late-stage retinal disease.